Senior Portfolio Manager Jay Jackley of Compass Capital Management says Thermo Fisher Scientific Inc. (TMO), the resulting company from the Thermo Electron and Fisher Scientific merger in 2006, is seeing strength in sales and profits as well as improvements in operating and net profit margins.
“The merger blended the strengths of the two companies really well,” Jackley said. “Over the last five years, they have grown sales and profits at a double-digit percentage rate annually. Over time, they have improved their operating margin, net profit margin and initiated a dividend. In 2009, the company made $5 a share, and they are projected to make $9.50 this year.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Jackley’s firm bought the stock in 2012 at $51, and it is currently trading around $118. Jackley says when they bought the stock it was down due to uncertainty surrounding the Affordable Care Act.
“At the end of the day, away from those headlines, there are companies like Thermo Fisher who are developing technologies, products and diagnostic tools to help the researchers find cures for various diseases. No matter what’s going on politically around health care, there remains a lot of human and financial capital devoted to trying to cure diseases. That will continue, regardless of what’s happening in Washington, D.C.,” Jackley said.
Thermo Fisher Scientific Inc. (TMO) Offers Long-Term-Value Potential with Life Technologies Corp. (LIFE) Acquisition
August 06, 2013
Thermo Fisher Scientific Inc. (TMO) Plays Into Health Care’s M&A Theme with Life Technologies Corp. (LIFE) Acquisition
August 19, 2013
Consistent Earnings Growth for Thermo Fisher Scientific Inc. (TMO)
February 08, 2016
Thermo Fisher Scientific Inc. (NYSE:TMO) a Defensive Play in Life Sciences
April 21, 2017
Itochu Corp (TYO:8001) and Sumitomo Mitsui Financial Grp, Inc. (ADR) (SMFG) Earn Double-Digit Profits, Pay 3% Dividend
September 16, 2013
